Studies examining Abelson/Moloney murine leukemia virus [A-MuLV(Mo)]-induced leukemia in mice have revealed that there is a marked variation in the susceptibility to disease among commonly used inbred strains of mice (1) . While nearly all strains examined develop characteristic disease symptoms after injection of newborn mice with the virus, most mouse strains are resistant when inoculated as adults. For example, C3H/HeN and C57BL/6 mice are almost completely resistant to tumor induction as adults, BALB/c and DBA/2 mice are among the most susceptible strains, and A/J mice show an intermediate-to low-level incidence. Although two susceptibility loci have been identified using inbred and hybrid mouse strains, the mechanism of tumor resistance remain unknown .
We have previously described the appearance of a cell surface glycoprotein, gp160", at high levels on virtually all in vitro (2) and in vivo (3) Abelson MuLV (A-MuLV)-induced B lineage tumors . After in vivo infection with A-MuLV(Mo), susceptible hosts develop a lymphoid replacement of the bone marrow, splenomegaly, and often lymphadenopathy, all due to proliferation and spread of malignant cells (4). We have shown (3) that the antigen 6C3Ag marks these cells and that the 6C3Ag+ cells score as transformed clonogenic cells in an in vitro agar colony assay. Because it was possible that one or more A-MuLV(Mo) resistance genes acts before or after expression of 6C3Ag on infectecd cells, we undertook an examination of the mouse strain distribution of expression of 6C3Ag on cells of A-MuLV(Mo)-infected hosts .
In this report we show that strains that are not susceptible to disease when injected as adults do not develop cells expressing high levels of 6C3Ag . In fact, expression of 6C3Ag by bone marrow, lymph node, or spleen cells is confined to diseased animals in susceptible strains. These data support our conclusion that high-level 6C3Ag expression is specific for the population of lymphocytes transformed by the virus in diseased animals, and supports the hypothesis that 
Materials and Methods
Mice. All inbred mice were bred at mouse colonies at Stanford University . The recombinant inbred mice CxB.H and CxB.G were purchased from The Jackson Laboratories, Bar Harbor, ME .
Reagents. mAb 6C3 has been described previously (2, 3) . Goat anti-rat Ig was purified from serum purchased from PelFreez (Rogers, AR) by protein A chromatography, and was subsequently conjugated to FITC by the method of Goding (5).
Staining. Immunofluorescent stainings and FACS analysis were carried out as previously described (3).
Virus and several low-susceptibility mouse strains (C3H/HeN, C57BL/6, A/J) with AMuLV(Mo) (1) . In addition, we injected two different ages of DBA/2 and C57BL/6 mice ; 3.5 wk and 8 wk after birth. Fig. I (left) shows that only DBA/2 mice injected 3-4 wk after birth develop Abelson disease symptoms and that only 3-4-wk-old DBA/2 mice developed 6C3Agh' bone marrow cells. 8-wk-old DBA/2 mice did not succumb to the virus and did not develop a significant percentage of 6C3Agh' cells in bone marrow (Fig. 1, right) . A low percentage (2%) of 6C3Agh' cells were found in one older DBA/2 mouse, which could reflect incipient disease. From this and other (3) experiments, there appears to be a complete correlation between disease and high-level expression of 6C3Ag on a high percentage of bone marrow cells. These animals were derived from inbreeding pairs of (C57BL/6 X BALB/c)F 2 (CxB) mice . As published (1), CxB.G is resistant to tumor induction while CxB.H is relatively susceptible (1). 3 wk after injection, CxB.H mice begin to develop signs of tumor, whereas CxB .G appeared normal . At this time, one injected animal of each strain was killed, and a bone marrow cell suspension was made and stained with mAb6C3 . Fig. 2A is the FACS profile derived from analysis of immunofluorescent staining of a CxB.G mouse, while Fig. 2B represents the profile from the diseased CxB.H strain ; only the CxB.H (susceptible) mouse showed 6C3Agh' cells. Thus the appearance of 6C3Agh' cells is predictive of the diseased state and genetic susceptibility to the disease . In total, three CxB.H mice with symptoms of Abelson disease were analyzed for 6C3Ag, and all display this pattern of expression (Fig. 2B) . With a longer latency, some of the CxB.G mice developed symptoms of Abelson disease. When analyzed for 6C3Ag, bone marrow, lymph node, and spleen cells from such mice were found to express high levels of the antigen (Fig. 3) . Therefore, we have not yet found a mouse with Abelson disease that lacks a population of cells expressing high levels of 6C3Ag, regardless of genetic resistance or susceptibility.
Discussion
Genetically linked susceptibility to A-MuLV(Mo) leukemogenesis in vivo appears to involve two independent loci, either of which modify the development of leukemia rather than cause regression of established tumors (1). Thus these restrictions probably limit events before the emergence of frankly leukemic cells. After integration of A-MuLV into host cells, viral-encoded gag-abl fusion protein is expressed as a cytoplasmic, plasma membrane-associated tyrosine kinase . This expression of the v-abl oncogene is not sufficient for full neoplastic transformation in vitro in liquid cultures, as proliferation of cells expressing gag-abl is dependent on bone marrow-derived stromal feeder cells characteristic of the Whitlock-Witte in vitro pre-B culture system (6) . These gag-abl + cells are 6C3Ag at this stage of development (2) . Fully malignant, feeder layer-independent pre-B leukemias emerge; these cells either are 6C3Agh' or give rise to progeny that become 6C3Agh' (G. F. Tidmarsh, manuscript in preparation) . Incidentally, the cloned stromal cells from Whitlock-Witte pre-B cultures that support growth of premalignant gag-abl' 6C3Ag-cells are themselves synthesizing and expressing high levels of cell surface 6C3Ag, providing evidence that the expression of 6C3Ag is linked to growth control of both normal and preneoplastic pre-B cells (Whitlock, Tidmarsh, Muller-Sieburg, and Weissman, manuscript submitted for publication) . Herein, we sought evidence as to whether genetically limited susceptibility to A-MuLV(Mo)-induced pre-B leukemia acted before or after the stage of 6C3Ag expression . Mouse strains genetically resistant to A-MuLV(Mo) develop neither 6C3Ag+ bone marrow cells nor Abelson leukemias, consistent with the model that restriction occurs before 6C3Ag expression at some earlier stage of neoplastic progression, perhaps after gag-abl expression in infected cells. It has recently (7) been shown that several other viral oncogenes, when expressed as cytoplasmic, membrane-associated phosphokinases, can induce pre-B leukemias after infection of bone marrow cells in vitro with a murine retrovirus vector (7) ; these include abl, src, fes, ras, and erb B. whether any (or all) of these are also genetically restricted as leukemogens in the mouse strains resistant to A-MuLV(Mo) . In contrast to these phosphokinase oncogenes, v-myc-containing vectors induce and c-myc-transgenic mice with immunoglobulin H chain enhancer sequences develop marrow-derived pre-B leukemias, and none of these are 6C3Ag+. It will be interesting to see whether these tumors also differ from the phosphokinase oncogene leukemogens by the abovedescribed mouse strain genetic restrictions .
In these and previously published experiments (2, 3) there is an absolute correlation between induction of Abelson disease and expression of cell surface 6C3Ag on presumably malignant cells. This is consistent with the hypothesis that expression of high levels of 6C3Ag on pre-B/early B cells is a marker for the malignant stage of neoplastic progression after A-MuLV(Mo) infection, and that proteins bearing 6C3Ag are directly involved in expression of the malignant phenotype in these cells.
The observation that 6C3Ag is undetectable in secondary lymphoid organs in the absence of disease, yet is readily detectable in these organs when they are lymphomatous makes the antigen an excellent marker for diagnosis of disease. Current efforts are directed toward developing polyclonal antisera and mAbs that recognize an analogous molecule on human tumors . Identification of such a determinant may be of potential benefit for diagnosis and/or therapy of pre-B cell or non-B/non-T cell leukemias and lymphomas in man.
Summary
Mice genetically susceptible or genetically resistant to the leukemogenic effects of A-MuLV(Mo) were tested for their expression of the B-lineage neoplastic transformation-associated antigen, 6C3Ag. Genetically resistant inbred strains and recombinant inbred lines developed neither cells expressing high levels of 6C3Ag (6C3Ag") in their hematolymphoid tissues nor Abelson leukemias. Genetically susceptible inbred strains and recombinant inbred lines developed high percentages of 6C3Ag" hematolymphoid cells concomitant with development of Abelson leukemias and lymphomas. Thus the genetically-determined resistance to A-MuLV(Mo) leukemogenesis appears to act at some step(s) after virus infection but before the stage of malignant progression, which is marked by 6C3Ag expression .
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